Alterity Therapeutics

ICYMI: an article recently published in the journal #Metallomics demonstrates that #ATH434 has the capacity to selectively target the pathogenic form of iron without impairing normal cellular iron trafficking or functions. ATH434 acts as an iron chaperone to redistribute this excess reactive iron, thereby reducing protein aggregation and oxidative stress in the brain and rescuing neuronal function. #ironchaperone #RedistributeReduceRescue

We are grateful that NeurologyLive has featured Dr Daniel Claassen on its #MindMoments podcast, for a conversation about the development of #ATH434 for the treatment of #MultipleSystemAtrophy. Click below to listen!

On World MSA Day, Alterity honors patients as well as the care partners, families and friends supporting those affected by Multiple System Atrophy. #WorldMSADay #MSA #MultipleSystemAtrophy

This past weekend, Alterity Therapeutics proudly participated in the International Congress of Parkinson's Disease and Movement Disorders (#MDSCongress), showcasing our commitment to advancing neurodegenerative disease treatments. With two oral presentations and four poster presentations, we highlighted the promising potential of our lead candidate, ATH434. CEO David Stamler remarked, “We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several presentations. Taken together, the data demonstrate the potential for ATH434 to modify disease progression and reduce disability in individuals living with MSA.” For more insights from David, check out the video below or read the full announcement here: https://bit.ly/3Na3q1e #NeurodegenerativeDiseases #Parkinsons #MultipleSystemAtrophy #MovementDisorders #MDS2024 #ATH434 #AlterityTherapeutics

Alterity's research will be presented in 4 posters and 2 oral platforms at the upcoming International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Philadelphia this coming weekend. We look forward to the opportunity to showcase the progress we have been making against neurodegenerative diseases such as #MSA. Details here: https://bit.ly/4e8N4Si #MDSIntlCongress #MDSCongress Photo: International Parkinson and Movement Disorder Society

Exciting news! Stockhead has featured Alterity Therapeutics and our groundbreaking efforts to develop a treatment that could potentially slow the progression of Parkinson's disease. We are thrilled to be making progress in the development of what could be the first treatment for #MSA and other degenerative diseases like #Parkinsons and #Alzheimers. We stand firm in our commitment to bringing hope to those affected by this debilitating diseases. Read the full article below #AlterityTherapeutics #MultipleSystemAtrophy #ParkinsonsDisease #MedicalResearch #Innovation

Alterity Therapeutics will present a webinar today for investors and shareholders hosted by MST Financial. CEO David Stamler will present the Company’s developments, including the recently announced interim data for the Phase 2 open-label study of ATH434 in Multiple System Atrophy. If you would like to join, please register here: https://bit.ly/3YgUbD3 #MSA #MultipleSystemAtrophy #ATH434

Alterity announces positive interim data from the ATH434-202 Phase 2 clinical trial in #MSA. Favorable clinical and biomarker outcomes in some patients suggest that #ATH434 has the potential to modify the course of this devastating condition. Read more here: https://bit.ly/467hst2 #multiplesystematrophy #clinicaltrial #raredisease #neurodegenerativedisease

Results from the bioMUSE natural history study have led to improved patient selection and endpoint development for Alterity's clinical trials. Re-watch our latest shareholder webinar to learn more about Alterity's work in creating an alternate future for people living with Multiple System Atrophy and other neurodegenerative diseases: https://bit.ly/3wZacCu #MSA #multiplesystematrophy #clinicaltrials

Alterity Therapeutics has released new data from the #bioMUSE natural history study in Multiple System Atrophy. #MSA CEO Dr David Stamler will host a webinar today to discuss these new findings and to provide insights into the company's current clinical program. If you would like to join, please register here: https://bit.ly/3yFXHMp